Send to

Choose Destination
J Am Acad Dermatol. 2002 Jun;46(6):945-7.

Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.

Author information

Department of Dermatology, Columbia-Presbyterian Medical Center, New York, New York, USA.


Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center